US7077129B2 - Dispenser with biased cover - Google Patents
Dispenser with biased cover Download PDFInfo
- Publication number
- US7077129B2 US7077129B2 US10/168,751 US16875102A US7077129B2 US 7077129 B2 US7077129 B2 US 7077129B2 US 16875102 A US16875102 A US 16875102A US 7077129 B2 US7077129 B2 US 7077129B2
- Authority
- US
- United States
- Prior art keywords
- cover
- storage
- biasing
- exit channel
- use position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 210000003813 thumb Anatomy 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 230000013011 mating Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 description 46
- -1 e.g. Chemical compound 0.000 description 23
- 239000000443 aerosol Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 6
- 229960004017 salmeterol Drugs 0.000 description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 5
- 229960002052 salbutamol Drugs 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229950000339 xinafoate Drugs 0.000 description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960004436 budesonide Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960000289 fluticasone propionate Drugs 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012858 resilient material Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UBLVUWUKNHKCJJ-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 UBLVUWUKNHKCJJ-ZSCHJXSPSA-N 0.000 description 1
- RZMCXMNNXGCFQG-DQEYMECFSA-N (2s)-3-[4-(4-carbamoylpiperidine-1-carbonyl)oxyphenyl]-2-[[(2s)-4-methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl]amino]propanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(OC(=O)N2CCC(CC2)C(N)=O)=CC=1)C(O)=O)C(=O)COC1=CC=CC=C1C RZMCXMNNXGCFQG-DQEYMECFSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/008—Electronic counters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D43/00—Lids or covers for rigid or semi-rigid containers
- B65D43/14—Non-removable lids or covers
- B65D43/22—Devices for holding in closed position, e.g. clips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D43/00—Lids or covers for rigid or semi-rigid containers
- B65D43/14—Non-removable lids or covers
- B65D43/24—Devices for retaining in open position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
Definitions
- the present invention relates to a dispenser for dispensing the contents thereof.
- the invention relates particularly to a dispenser for the administration of medicament to a patient.
- medicaments contained in an aerosol for example, in the treatment of respiratory disorders. It is also known to use for such treatment, medicaments which are contained in an aerosol and are administered to a patient by means of an inhalation device comprising a tubular housing or sleeve in which the aerosol container is located and an outlet tube leading out of the tubular housing.
- inhalation devices are generally referred to as metered dose inhalers (MDIs).
- MDIs metered dose inhalers
- the aerosol containers used in such inhalation devices are designed to deliver a predetermined dose of medicament upon each actuation by means of an outlet valve member at one end which can be opened either by depressing the valve member while the container is held stationary or by depressing the container while the valve member is held stationary.
- the aerosol container is placed in the tubular housing with the outlet valve member of the container communicating via a support with the outlet tube, for example a nozzle or mouthpiece.
- a support with the outlet tube
- the patient When used for dispensing medicaments, for example in bronchodilation therapy, the patient then holds the housing in a more or less upright condition and the mouthpiece or nozzle of the inhalation device is placed in the mouth or nose of the patient.
- the aerosol container is pressed towards the support to dispense a dose of medicament from the container which is then inhaled by the patient.
- dispensers for the delivery of inhalable medicament.
- such dispensers comprise pre-metered doses of powdered medicament, for example in capsules or blisters.
- such dispensers comprise a reservoir of powdered medicament from which doses are metered prior to or concurrent with the delivery process.
- the device may be designed for passive release of medicament, where the medicament is simply made available at a delivery position for aerosolisation in response to the inhalation of the patient.
- an active release mechanism may be used whereby a ‘puff’ of compressed gas or air is provided to the delivery position to assist in aerosolisation of the powder prior to or concurrent with the inhalation of the patient.
- active DPIs active release dry powder inhalers
- the source of the compressed gas or air is generally an aerosol container.
- syringes for the delivery of injectable medicament to a patient.
- Traditional syringes rely on puncturing of the patient's skin by a hollow needle through which the injectable medicament (in solution or suspension form) is delivered to the muscle or tissue of the patient.
- injectable medicament in solution or suspension form
- Recently developed needleless systems for the delivery of injectables employ high velocity injection of particle formulated drugs or vaccine through the skin and into any physically accessible tissue.
- Other needleless systems employ similar high velocity injection of drug or vaccine coated on to a suitable carrier particle.
- medicament dispenser such as bottles, tubes or vials
- exit channel or nozzle
- the body of the device is held by the patient and the exit channel (or nozzle) of the device is placed in the mouth/nose or on the skin, or in the palm of the patient's hand.
- the exit channel is provided with some kind of protective cover.
- the cover desirably acts both to prevent build-up of dirt on the exit channel and to prevent ingress of dirt into the body of the device through the channel, which might then be subject to administration by a patient. It is desirable for the cover to be joined to the body of the device so that it cannot be separated from the device.
- the applicants have now found that this problem can be overcome by the use of a cover which has biasing means acting upon it.
- the biasing means enables the cover to move in a reversible manner directly from the in-use position, when the exit channel is fully exposed, to the storage position, wherein the exit channel is fully protected by the cover.
- a further advantage of the present invention is that the exit channel cover is provided with a clear portion to enable viewing of the exit channel when the exit channel is fully protected. This clear portion also enables viewing of a dose counter or alphanumeric display when the exit channel is fully exposed.
- the present invention has utility in protecting the exit channel of a wide range of dispensers, including food and toiletry dispensers.
- a dispenser comprising a body for receipt of a carrier for a composition; an exit channel definable by the body for passage of the composition to a user; a cover for the exit channel reversibly movable between a storage position in which the cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed; and biasing means acting on the cover when the cover is not in said in-use or storage positions, to bias the cover towards either the in-use position or the storage position.
- the dispenser additionally comprises a control element to control the amount of biasing energy acting on the cover.
- control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions.
- the biasing energy curve reaches a maximum when the cover is at a definite point between the starting and in-use positions. More preferably, the biasing energy curve has a single maximum.
- the biasing energy curve is symmetrical.
- the biasing energy curve is asymmetrical.
- control element comprises a cam surface and a cam follower.
- control element comprises a ramp.
- the biasing means comprises a spring.
- the biasing means comprises an articulated assembly.
- the biasing means comprises resilient material.
- the biasing means comprises a pressure based system.
- the pressure based system is a pneumatic system. More preferably, the pressure based system is a hydraulic system.
- the cover is reversibly lockable in the storage or in-use positions.
- the cover is rotatably movable.
- the cover is slidably movable.
- the biasing means comprises a spring
- the control element comprises a cam surface and cam follower
- the biasing means comprises an articulated assembly and the control element comprises a ramp.
- the biasing means comprises a resilient plug movable between two sockets and the control element comprises the surface between the two sockets.
- the cover is movable by a sliding thumb motion.
- the cover is movable by one-handed operation. More preferably, the cover is movable by a right-handed or left-handed user.
- the dispenser additionally comprises a carrier.
- the carrier is selected from the group consisting of aerosol container, tube, bottle, phial, vial, blister strip and capsule.
- the carrier additionally comprises a composition.
- the physical form of the medicament is selected from the group consisting of cream, ointment, powder, solution, suspension, tablet and emulsion.
- the carrier is an aerosol container.
- the aerosol container additionally comprises a suspension of a composition in a propellant.
- the propellant comprises liquefied HFA134a, HFA-227 or carbon dioxide.
- the carrier is a dry-powder container.
- the dry-powder container comprises a composition and optionally excipient in dry-powder form.
- the medicament carrier is a liquid container.
- the liquid container comprises a solution of composition in a solvent.
- the composition comprises a medicament.
- the medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.
- the cover has a clear portion to enable the user to see the location of the exit channel when in the storage position.
- the dispenser is additionally provided with a dose counter display.
- the dose counter display is visible through the clear portion of the cover when the cover is in the in-use position.
- the dispenser is additionally provided with an alphanumeric display. More preferably, the alphanumeric display is visible through the clear portion of the cover when the cover is in the in-use position.
- the composition comprises a foodstuff.
- the foodstuff is selected from the group consisting of tomato puree, mustard, fish paste, meat paste, sweet sauce, savoury sauce and pate.
- the composition comprises a toiletry.
- the toiletry is selected from the group consisting of toothpaste, deodorant, soap, eye drop, shampoo, moisturising cream and hand cream.
- dispenser according to the present invention for dispensing medicament.
- kits of parts comprising a dispenser according to the present invention and a medicament carrier.
- FIG. 1 a shows a perspective view of medicament dispenser in accord with the present invention with the cover in the in-use position.
- FIG. 1 b shows a perspective view of an medicament dispenser in accord with the present invention with the cover in the storage position.
- FIG. 2 a shows a sectional view through a shaft containing a first biasing means and control element suitable for the device of FIGS. 1 a and 1 b , but not exclusive thereto, when the cover is in the storage or in-use positions.
- FIG. 2 b is a sectional view through a shaft containing a first biasing means and control element suitable for the device of FIGS. 1 a and 1 b , but not exclusive thereto, when the cover is moving between the storage and in-use positions and at the position of maximum biasing energy.
- FIG. 3 shows a perspective view of a second biasing means and control element suitable for the device of FIGS. 1 a and 1 b , but not exclusive thereto.
- FIG. 4 a shows a sectional view of the biasing means and control element of FIG. 3 when the cover is in the in-use or storage positions.
- FIG. 4 b shows a sectional view of the biasing means and control element of FIG. 3 when the cover is moving between the in-use or storage positions.
- FIG. 4 c shows a sectional view of the biasing means and control element of FIG. 3 when the cover is in the opposite position to that of FIG. 4 a.
- FIG. 5 a shows a sectional view of a third biasing means and control element suitable for the device of FIGS. 1 a and 1 b , but not exclusive thereto.
- FIG. 5 b shows a sectional view of the third biasing means and control element of FIG. 5 a , rotated through 90°.
- FIG. 6 shows a perspective view of the cover of FIGS. 1 a and 1 b showing the location of the biasing means and control element of FIGS. 5 a and 5 b.
- FIG. 7 a shows a perspective view of a medicament dispenser in accord with the present invention with the cover in the storage position.
- FIG. 7 b shows a perspective view of a medicament dispenser in accord with the present invention with the cover in the in-use position.
- FIGS. 1 a and 1 b show a medicament dispenser according to the present invention comprising a body 10 , an exit channel or mouthpiece 20 , an exit channel or mouthpiece cover 25 and pivoting means 30 to connect the cover 25 to the body 10 and to pivot the cover 25 with respect to the body 10 .
- the pivoting means 30 are also involved in the biasing mechanism and may be directly or indirectly connected to the biasing means and control element or may consist of a shaft connecting to both sides of the cover and containing the biasing means and control element.
- a display 40 may be additionally present on the device and can be used to indicate the number of doses remaining in or dispensed from a medicament carrier (hidden) contained within the body 10 .
- the mouthpiece cover 25 can be made from a clear material to enable the user of the device to see the display 40 when the cover 25 is in the in-use position ( FIG. 1 a ) and to see the location of the mouthpiece 20 when the cover 25 is in the storage position ( FIG. 1 b ).
- the device is shaped so that one-handed operation is facilitated whereby the palm and fingers of one hand can grip the device and the cover 25 is movable by a motion of the thumb of the same hand.
- One-handed operation of the device is possible by either a right-handed or left-handed user.
- FIGS. 2 a and 2 b show a biasing mechanism contained within a shaft 145 .
- the ends 146 , 147 of the shaft 145 are connectable to the pivoting means shown in FIGS. 1 a and 1 b .
- Located in, but not fixed to, the shaft are two cams 152 , 154 separated by a spring 155 .
- Fixed to each end 146 , 147 of the shaft 145 are cam followers 156 , 158 .
- the spring 155 When the cover is in the storage or in-use position, the spring 155 is relaxed and the cams 152 , 154 and cam followers 156 , 158 are positioned as shown in FIG. 2 a .
- the cam followers 156 , 158 are shaped so that in one position they have a shape complementary to that of the ends of the cams 152 , 154 and when rotated have a shape which is non-complementary to that of the ends of the cams 152 , 154 .
- the cam followers 156 , 158 As the cam followers 156 , 158 are rotated, due to movement of the cover, the cams 152 , 154 are pushed together by the cam followers 156 , 158 and this movement compresses the spring 155 , increasing the biasing energy available.
- the biasing energy curve defined by movement of the cam followers 156 , 158 relative to the cams 152 , 154 is symmetrical.
- the cam may define an asymmetrical profile wherein the biasing curve is engineered to favour either the in-use position or the storage position.
- Movement of the cam followers 156 , 158 by an angle of less than 90° relative to the cams 152 , 154 results in movement of the cam followers 156 , 158 (and hence the shaft and cover) back to their starting position.
- the amount of biasing energy available increases with the angle of movement of the cam followers 156 , 158 , due to increased compression of the spring 155 , so that maximum biasing energy is available when the cam followers 156 , 158 have moved exactly 90° relative to the cams 152 , 154 .
- This arrangement of the cams 152 , 154 and cam followers is shown in FIG. 2 b.
- Movement of the cam followers 156 , 158 by an angle greater than 90 ° results in continued movement of the cam followers 156 , 158 through a further 90° until the spring 155 is relaxed and the biasing energy available is back to zero. This 180° movement results in switching of the cover from the storage position to the in-use position or vice versa.
- FIG. 3 shows a biasing mechanism comprising an articulated assembly 260 and a ramp 270 .
- the articulated assembly 260 is connectable with the pivoting means shown in FIGS. 1 a and 1 b so that movement of the cover results in movement of the articulated assembly 260 .
- the ramp 270 is fixed to an internal portion of the body of the medicament dispenser.
- FIGS. 4 a , 4 b and 4 c The movement of the articulated assembly is shown by a sectional view in FIGS. 4 a , 4 b and 4 c .
- the articulated assembly 360 When the cover is in the in-use and storage positions the articulated assembly 360 is located at the bottom of the ramp 370 and the biasing energy is zero ( FIG. 4 a ). Movement of the cover results in movement of the articulated assembly 360 up the ramp 370 . If the articulated assembly 360 is moved partially up one side of the ramp 370 then the articulated assembly 360 will move back down the ramp 370 to its starting position which has the minimum level of biasing energy. The position of maximum biasing energy is reached when the articulated assembly 360 reaches the highest point of the ramp 370 ( FIG. 4 b ). When the articulated assembly 360 passes this point then the cover is biased towards the other position ( FIG. 4 c ).
- FIGS. 5 a and 5 b A sectional view of a plug and socket biasing mechanism is shown in FIGS. 5 a and 5 b .
- FIG. 5 a shows two segments 490 , 492 , one of which contains two double sets of sockets 486 , 488 and the other which has the plugs 482 , 484 .
- the plugs 482 , 484 occupy one set of the sockets 486 .
- the plugs 482 , 484 are composed of resilient material so that when the cover is moved, the plugs 482 , 484 are pushed out of one set of sockets 486 and along the surface 485 between the two sets of sockets 486 , 488 until they reach the next set of sockets 488 as shown in FIG.
- the maximum level of biasing energy is reached at the mid point of the surface 485 between the sets of sockets 486 , 488 .
- the plugs 482 , 484 pass through this point then they will move to the other set of sockets 488 ; however if the plugs 482 , 484 only move part of the way towards this mid point then they will be biased to return to their starting position.
- the distance between the sets of sockets 486 , 488 defines the amount of biasing.
- FIG. 6 shows the location of the sockets of FIGS. 5 a and 5 b on the cover 525 of the device of FIGS. 1 a and 1 b .
- the biasing mechanism (not shown) is directly involved in the pivoting of the cover 525 .
- Each side of the cover has two sets of double sockets 586 , 588 , arranged as shown in FIG. 6 and these sets of sockets define the two positions of the cover 525 : the storage and in-use positions.
- FIGS. 7 a and 7 b show a medicament dispenser, in the form of tube 690 , for dispensing medicament according to the present invention.
- the tube 690 comprises a body 610 , exit channel or nozzle 620 , cover 625 and pivoting means 630 to connect the cover 625 to the nozzle 620 .
- the cover 625 may be connected to the body 610 by pivoting means 630 .
- the cover 625 is free to pivot with respect to the body 610 .
- the pivoting means 630 are also involved in the biasing mechanism and may be directly or indirectly connected to the biasing means and control element or may consist of a shaft connecting to both sides of the cover and containing the biasing means and control element.
- the tube 690 is in the storage-position, with the cover 625 protecting exit channel or nozzle 620 .
- a lid 626 which may be composed of aluminium foil or a suitable plastic, seals the orifice 628 of nozzle 620 .
- Cover 625 is movable, by a motion of the thumb of the user's hand holding tube 690 , to the in-use position ( FIG. 7 b ) thereby exposing lid 626 which may be peeled from orifice 628 .
- Medicament may be dispensed from tube 690 by squeezing body 610 in the palm of the user's hand, thereby forcing medicament in the form of ointment or cream from nozzle 620 .
- Cover 625 is returned to the storage position ( FIG. 7 a ) by the action of the user's thumb of the hand gripping the tube 690 .
- One-handed operation of the medicament container or tube is therefore possible by either a right-handed or left-handed user.
- any of the parts of the dispenser which contact the medicament may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto.
- Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
- the medicament dispenser of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease.
- Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (e.g. as the sodium salt), ketotifen or nedocromil (e.g.
- antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
- antihistamines e.g., methapyrilene
- anti-inflammatories e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g.
- antitussives e.g., noscapine
- bronchodilators e.g., albuterol (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g.
- bromide as bromide
- tiotropium as bromide
- atropine or oxitropium hormones, e.g., cortisone, hydrocortisone or prednisolone
- xanthines e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline
- therapeutic proteins and peptides e.g., insulin or glucagon
- vaccines diagnostics and gene therapies.
- the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.
- Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
- Medicaments can also be delivered in combinations.
- Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (e.g. as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide.
- a particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt).
- a further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Biophysics (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Closures For Containers (AREA)
- Medicinal Preparation (AREA)
- Manipulator (AREA)
- Cosmetics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
There is provided a dispenser comprising a body for receipt of a carrier for a composition; an exit channel definable by the body for passage of the composition to a user; a cover for the exit channel reversibly movable between a storage position in which the cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed. Biasing means act on the cover when the cover is not in the in-use or storage positions, to bias the cover towards either the in-use position or the storage position.
Description
This application is filed pursuant to 35 USC 371 as a U.S. National Phase Application of Ser. No. PCT/EP00/12884 filed Dec. 18, 2000, which claims priority from GB 9930602.9 filed Dec. 24, 1999 in the United Kingdom.
The present invention relates to a dispenser for dispensing the contents thereof. The invention relates particularly to a dispenser for the administration of medicament to a patient.
It is well known to treat patients with medicaments contained in an aerosol, for example, in the treatment of respiratory disorders. It is also known to use for such treatment, medicaments which are contained in an aerosol and are administered to a patient by means of an inhalation device comprising a tubular housing or sleeve in which the aerosol container is located and an outlet tube leading out of the tubular housing. Such inhalation devices are generally referred to as metered dose inhalers (MDIs). The aerosol containers used in such inhalation devices are designed to deliver a predetermined dose of medicament upon each actuation by means of an outlet valve member at one end which can be opened either by depressing the valve member while the container is held stationary or by depressing the container while the valve member is held stationary. In the use of such devices, the aerosol container is placed in the tubular housing with the outlet valve member of the container communicating via a support with the outlet tube, for example a nozzle or mouthpiece. When used for dispensing medicaments, for example in bronchodilation therapy, the patient then holds the housing in a more or less upright condition and the mouthpiece or nozzle of the inhalation device is placed in the mouth or nose of the patient. The aerosol container is pressed towards the support to dispense a dose of medicament from the container which is then inhaled by the patient.
It is also known to use dry powder inhalation devices for the delivery of inhalable medicament. In one aspect, such dispensers comprise pre-metered doses of powdered medicament, for example in capsules or blisters. In another aspect, such dispensers comprise a reservoir of powdered medicament from which doses are metered prior to or concurrent with the delivery process. In either case, the device may be designed for passive release of medicament, where the medicament is simply made available at a delivery position for aerosolisation in response to the inhalation of the patient. Alternatively, an active release mechanism may be used whereby a ‘puff’ of compressed gas or air is provided to the delivery position to assist in aerosolisation of the powder prior to or concurrent with the inhalation of the patient. Such devices are generally called active release dry powder inhalers (active DPIs). The source of the compressed gas or air is generally an aerosol container.
It is also well known to use syringes for the delivery of injectable medicament to a patient. Traditional syringes rely on puncturing of the patient's skin by a hollow needle through which the injectable medicament (in solution or suspension form) is delivered to the muscle or tissue of the patient. Recently developed needleless systems for the delivery of injectables employ high velocity injection of particle formulated drugs or vaccine through the skin and into any physically accessible tissue. Other needleless systems employ similar high velocity injection of drug or vaccine coated on to a suitable carrier particle.
Other forms of medicament dispenser, such as bottles, tubes or vials, are known in the art, which comprise an exit channel (or nozzle) for dispensing medicament therefrom. In a typical dispensing operation using any of the above devices, the body of the device is held by the patient and the exit channel (or nozzle) of the device is placed in the mouth/nose or on the skin, or in the palm of the patient's hand.
When not in use it is desirable, from a hygiene standpoint, that the exit channel is provided with some kind of protective cover. The cover desirably acts both to prevent build-up of dirt on the exit channel and to prevent ingress of dirt into the body of the device through the channel, which might then be subject to administration by a patient. It is desirable for the cover to be joined to the body of the device so that it cannot be separated from the device.
Patient trials of various medicament dispensers have shown that patients do not always fully expose the exit channel before attempting to use the device or fail to fully protect it when the device is not in use.
The applicants have now found that this problem can be overcome by the use of a cover which has biasing means acting upon it. The biasing means enables the cover to move in a reversible manner directly from the in-use position, when the exit channel is fully exposed, to the storage position, wherein the exit channel is fully protected by the cover.
A further advantage of the present invention is that the exit channel cover is provided with a clear portion to enable viewing of the exit channel when the exit channel is fully protected. This clear portion also enables viewing of a dose counter or alphanumeric display when the exit channel is fully exposed.
The Applicants have also found that the present invention has utility in protecting the exit channel of a wide range of dispensers, including food and toiletry dispensers.
According to one aspect of the present invention there is provided a dispenser comprising a body for receipt of a carrier for a composition; an exit channel definable by the body for passage of the composition to a user; a cover for the exit channel reversibly movable between a storage position in which the cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed; and biasing means acting on the cover when the cover is not in said in-use or storage positions, to bias the cover towards either the in-use position or the storage position.
In one aspect, the dispenser additionally comprises a control element to control the amount of biasing energy acting on the cover.
Preferably the control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions. Preferably the biasing energy curve reaches a maximum when the cover is at a definite point between the starting and in-use positions. More preferably, the biasing energy curve has a single maximum.
In one aspect, the biasing energy curve is symmetrical.
In another aspect, the biasing energy curve is asymmetrical.
In a further aspect, the control element comprises a cam surface and a cam follower.
In one aspect, the control element comprises a ramp.
In another aspect, the biasing means comprises a spring.
In a further aspect, the biasing means comprises an articulated assembly.
Preferably, the biasing means comprises resilient material.
In one aspect, the biasing means comprises a pressure based system. Preferably, the pressure based system is a pneumatic system. More preferably, the pressure based system is a hydraulic system.
In another aspect, the cover is reversibly lockable in the storage or in-use positions.
In one aspect, the cover is rotatably movable. Preferably, the cover is slidably movable.
In a further aspect, the biasing means comprises a spring, and the control element comprises a cam surface and cam follower.
In another aspect, the biasing means comprises an articulated assembly and the control element comprises a ramp.
In one aspect, the biasing means comprises a resilient plug movable between two sockets and the control element comprises the surface between the two sockets.
In another aspect, the cover is movable by a sliding thumb motion. Preferably the cover is movable by one-handed operation. More preferably, the cover is movable by a right-handed or left-handed user.
In one aspect, the dispenser additionally comprises a carrier. Preferably the carrier is selected from the group consisting of aerosol container, tube, bottle, phial, vial, blister strip and capsule.
In another aspect, the carrier additionally comprises a composition.
Preferably, the physical form of the medicament is selected from the group consisting of cream, ointment, powder, solution, suspension, tablet and emulsion.
Preferably, the carrier is an aerosol container.
More preferably, the aerosol container additionally comprises a suspension of a composition in a propellant. More preferably, the propellant comprises liquefied HFA134a, HFA-227 or carbon dioxide.
In another aspect, the carrier is a dry-powder container.
Preferably, the dry-powder container comprises a composition and optionally excipient in dry-powder form.
Optionally, the medicament carrier is a liquid container. Preferably, the liquid container comprises a solution of composition in a solvent.
In one aspect, the composition comprises a medicament.
Preferably, the medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.
In another aspect, the cover has a clear portion to enable the user to see the location of the exit channel when in the storage position.
In a further aspect, the dispenser is additionally provided with a dose counter display.
Preferably, the dose counter display is visible through the clear portion of the cover when the cover is in the in-use position.
Preferably, the dispenser is additionally provided with an alphanumeric display. More preferably, the alphanumeric display is visible through the clear portion of the cover when the cover is in the in-use position.
In one aspect, the composition comprises a foodstuff. Preferably, the foodstuff is selected from the group consisting of tomato puree, mustard, fish paste, meat paste, sweet sauce, savoury sauce and pate.
In another aspect, the composition comprises a toiletry. Preferably, the toiletry is selected from the group consisting of toothpaste, deodorant, soap, eye drop, shampoo, moisturising cream and hand cream.
In another aspect of the present invention, there is provided the use of dispenser according to the present invention for dispensing medicament.
In a further aspect of the present invention there is provided a kit of parts comprising a dispenser according to the present invention and a medicament carrier.
The invention will now be described with reference to the accompanying drawings in which:
A display 40 may be additionally present on the device and can be used to indicate the number of doses remaining in or dispensed from a medicament carrier (hidden) contained within the body 10. The mouthpiece cover 25 can be made from a clear material to enable the user of the device to see the display 40 when the cover 25 is in the in-use position (FIG. 1 a) and to see the location of the mouthpiece 20 when the cover 25 is in the storage position (FIG. 1 b).
The device is shaped so that one-handed operation is facilitated whereby the palm and fingers of one hand can grip the device and the cover 25 is movable by a motion of the thumb of the same hand. One-handed operation of the device is possible by either a right-handed or left-handed user.
When the cover is in the storage or in-use position, the spring 155 is relaxed and the cams 152, 154 and cam followers 156, 158 are positioned as shown in FIG. 2 a. The cam followers 156, 158 are shaped so that in one position they have a shape complementary to that of the ends of the cams 152, 154 and when rotated have a shape which is non-complementary to that of the ends of the cams 152, 154. As the cam followers 156, 158 are rotated, due to movement of the cover, the cams 152, 154 are pushed together by the cam followers 156, 158 and this movement compresses the spring 155, increasing the biasing energy available. The biasing energy curve defined by movement of the cam followers 156, 158 relative to the cams 152, 154 is symmetrical. Alternatively the cam may define an asymmetrical profile wherein the biasing curve is engineered to favour either the in-use position or the storage position.
Movement of the cam followers 156, 158 by an angle of less than 90° relative to the cams 152, 154 results in movement of the cam followers 156, 158 (and hence the shaft and cover) back to their starting position. The amount of biasing energy available increases with the angle of movement of the cam followers 156, 158, due to increased compression of the spring 155, so that maximum biasing energy is available when the cam followers 156, 158 have moved exactly 90° relative to the cams 152, 154. This arrangement of the cams 152, 154 and cam followers is shown in FIG. 2 b.
Movement of the cam followers 156, 158 by an angle greater than 90° results in continued movement of the cam followers 156, 158 through a further 90° until the spring 155 is relaxed and the biasing energy available is back to zero. This 180° movement results in switching of the cover from the storage position to the in-use position or vice versa.
The movement of the articulated assembly is shown by a sectional view in FIGS. 4 a, 4 b and 4 c. When the cover is in the in-use and storage positions the articulated assembly 360 is located at the bottom of the ramp 370 and the biasing energy is zero (FIG. 4 a). Movement of the cover results in movement of the articulated assembly 360 up the ramp 370. If the articulated assembly 360 is moved partially up one side of the ramp 370 then the articulated assembly 360 will move back down the ramp 370 to its starting position which has the minimum level of biasing energy. The position of maximum biasing energy is reached when the articulated assembly 360 reaches the highest point of the ramp 370 (FIG. 4 b). When the articulated assembly 360 passes this point then the cover is biased towards the other position (FIG. 4 c).
A sectional view of a plug and socket biasing mechanism is shown in FIGS. 5 a and 5 b. FIG. 5 a shows two segments 490, 492, one of which contains two double sets of sockets 486, 488 and the other which has the plugs 482, 484. When the cover is in the storage or in-use position, the plugs 482, 484 occupy one set of the sockets 486. The plugs 482, 484 are composed of resilient material so that when the cover is moved, the plugs 482, 484 are pushed out of one set of sockets 486 and along the surface 485 between the two sets of sockets 486, 488 until they reach the next set of sockets 488 as shown in FIG. 5 b. The maximum level of biasing energy is reached at the mid point of the surface 485 between the sets of sockets 486, 488. When the plugs 482, 484 pass through this point then they will move to the other set of sockets 488; however if the plugs 482, 484 only move part of the way towards this mid point then they will be biased to return to their starting position. The distance between the sets of sockets 486, 488 defines the amount of biasing.
In FIG. 7 a the tube 690 is in the storage-position, with the cover 625 protecting exit channel or nozzle 620. A lid 626, which may be composed of aluminium foil or a suitable plastic, seals the orifice 628 of nozzle 620. Cover 625 is movable, by a motion of the thumb of the user's hand holding tube 690, to the in-use position (FIG. 7 b) thereby exposing lid 626 which may be peeled from orifice 628. Medicament may be dispensed from tube 690 by squeezing body 610 in the palm of the user's hand, thereby forcing medicament in the form of ointment or cream from nozzle 620. Cover 625 is returned to the storage position (FIG. 7 a) by the action of the user's thumb of the hand gripping the tube 690. One-handed operation of the medicament container or tube is therefore possible by either a right-handed or left-handed user.
It may be appreciated that any of the parts of the dispenser which contact the medicament may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto. Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
The medicament dispenser of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease. Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (e.g. as the sodium salt), ketotifen or nedocromil (e.g. as the sodium salt); antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g. as the acetonide) or 6α, 9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-androsta-1,4-diene-17β-carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g. as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (e.g. as acetate), reproterol (e.g. as hydrochloride), rimiterol, terbutaline (e.g. as sulphate), isoetharine, tulobuterol or 4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone; adenosine 2a agonists, e.g. 2R,3R,4S,5R)-2-[6-Amino-2-(1S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol (e.g. as maleate); α4 integrin inhibitors e.g. (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid (e.g. as free acid or potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (e.g. as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; vaccines, diagnostics and gene therapies. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant. Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (e.g. as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide. A particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).
It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following claims:
Claims (15)
1. A dispenser comprising:
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the control element comprises a cam surface and a cam follower.
2. A dispenser comprising
a body for receipt of a carrier for a composition; an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the control element comprises a ramp.
3. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, wherein the biasing element comprises a pressure based system, and wherein the pressure based system is a pneumatic system.
4. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, wherein the biasing element comprises a pressure based system, and wherein the pressure based system is a hydraulic system.
5. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the cover is slidably movable.
6. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the biasing element comprises a spring, and the control element comprises a cam surface and cam follower.
7. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the biasing element comprises an articulated assembly and the control element comprises a ramp.
8. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the cover is movable by sliding thumb motion.
9. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the cover has a clear portion to enable the user to see the location of the exit channel when in the storage position.
10. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body for passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the dispenser is additionally provided with a dose counter display.
11. A dispenser according to claim 10 , wherein said dose counter display is visible through the clear portion of the cover when the cover is in the in-use position.
12. A dispenser comprising
a body for receipt of a carrier for a composition;
an exit channel definable by said body passage of said composition to a user;
a cover for said exit channel reversibly movable between a storage position in which said cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed;
a biasing element capable of generating a biasing energy for acting on the cover when the cover is not in said in-use or storage positions, capable of biasing the cover towards either the in-use position or the storage position depending on the location of the cover between its storage and in-use positions; and
a control element cooperatively engaging the biasing element to control the direction of the bias acting on the cover,
wherein said control element defines a biasing energy curve varying according to the proximity of the cover to the storage and in-use positions, and wherein the biasing energy curve has a maximum when the cover is at a defined point between the storage and the in-use position such as to bias the cover away from said defined point and towards either the in-use position or the storage position, and wherein the dispenser is additionally provided with an alphanumeric display.
13. A dispenser according to claim 12 , wherein the alphanumeric display is visible through the clear portion of the cover when the cover is in the in-use position.
14. A dispenser comprising:
(a) a body in receipt of a carrier for a composition, said body defining an exit channel for passage of said composition to a user;
(b) a cover for said exit channel, said cover defining opposing interior surfaces;
(c) at least one inwardly directed cam follower about which said cover pivots, said cam follower defined by or connected to said interior surface, said cam follower having a cam follower face;
(d) a hollow shaft associated with said body, said hollow shaft at least partially enclosing a spring, at least one cam and said cam follower face, said spring communicating with said cam and said cam defining a mating face which abuts said cam follower face;
wherein said cover is reversibly and pivotally movable between a storage position, in which said cover fully protects the exit channel, to an in-use position, wherein the exit channel is exposed; and wherein movement of said cover rotates said cam follower face causing partial distancing of the cam follower and cam mating face and compression of said spring to create a biasing force biasing said cover toward either the storage position or in use position, depending on the degree of rotation of the cover.
15. The dispenser of claim 14 , wherein said mating face of said cam further comprises a surface defining a peak and a trough, and said cam follower face has a surface defining a corresponding peak and trough, and wherein the peak of one surface resides in the trough of the other surface when said cover is the in-use position or in the storage position, and the distance between the mating face and the cam follower face is at a minimum.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9930302.9 | 1999-12-24 | ||
GBGB9930602.9A GB9930602D0 (en) | 1999-12-24 | 1999-12-24 | Inhalation device |
PCT/EP2000/012884 WO2001047590A1 (en) | 1999-12-24 | 2000-12-18 | Dispenser with biased cover |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030010337A1 US20030010337A1 (en) | 2003-01-16 |
US7077129B2 true US7077129B2 (en) | 2006-07-18 |
Family
ID=10867011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/168,751 Expired - Fee Related US7077129B2 (en) | 1999-12-24 | 2000-12-18 | Dispenser with biased cover |
Country Status (8)
Country | Link |
---|---|
US (1) | US7077129B2 (en) |
EP (1) | EP1239906B1 (en) |
JP (1) | JP2003518418A (en) |
AT (1) | ATE240760T1 (en) |
AU (1) | AU3726201A (en) |
DE (1) | DE60002920T2 (en) |
GB (1) | GB9930602D0 (en) |
WO (1) | WO2001047590A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060131350A1 (en) * | 2004-12-22 | 2006-06-22 | Schechter Alan M | Apparatus for dispensing pressurized contents |
US20080196718A1 (en) * | 2005-07-28 | 2008-08-21 | Glaxo Group Limited | Medicament Dispenser |
US20090183744A1 (en) * | 2008-01-22 | 2009-07-23 | Paul Graham Hayton | Hand-Held dispensing device |
US7651009B2 (en) | 2004-08-16 | 2010-01-26 | Warner Lambert Company Llc | Liquid dispensing device |
USD666097S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666099S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666096S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666098S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666493S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD666492S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2538876C (en) * | 2006-03-08 | 2013-01-22 | Gotohti.Com Inc. | Removable nozzle shield for fluid dispenser |
CA2567912C (en) | 2006-11-14 | 2014-12-09 | Gotohti.Com Inc. | Removable lever assembly for fluid dispenser |
EP2244771A4 (en) * | 2008-01-23 | 2013-11-06 | Astrazeneca Ab | A medicament-containing dispenser provided with a display for presenting indicia to a user |
PL2558148T3 (en) * | 2010-04-13 | 2016-09-30 | Dry powder inhaler mouthpiece button | |
WO2014052263A1 (en) | 2012-09-27 | 2014-04-03 | 3M Innovative Properties Company | A dispensing assembly |
USD776255S1 (en) * | 2014-06-17 | 2017-01-10 | Koninklijke Philips N.V. | Handheld respiratory device |
USD771798S1 (en) * | 2014-06-17 | 2016-11-15 | Koninklijke Philips N.V. | Handheld respiratory device |
USD776254S1 (en) * | 2014-06-17 | 2017-01-10 | Koninklijke Phlips N.V. | Handheld respiratory device |
USD805999S1 (en) * | 2016-07-28 | 2017-12-26 | William G. Ellis | Fang attachment to vehicle |
EP3321211A1 (en) * | 2016-11-09 | 2018-05-16 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhaler device comprising a fixable lid assembly |
EP4003471B1 (en) * | 2019-07-24 | 2024-09-04 | Trudell Medical International Inc. | Portable holding chamber for pressurized metered dose inhaler |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2161863A (en) | 1984-07-16 | 1986-01-22 | Realex Corp | Dispenser for pasty products |
US4749351A (en) * | 1986-06-30 | 1988-06-07 | Fgm Enterprises, Inc. | Lighter |
EP0341967A2 (en) | 1988-05-09 | 1989-11-15 | Bespak plc | Dispensing apparatus for nasal administration of an aerosol product |
US4949875A (en) | 1986-02-18 | 1990-08-21 | Youti Kuo | Dispenser with integrated cover for paste-like material |
US5408994A (en) * | 1990-11-14 | 1995-04-25 | Minnesota Mining And Manufacturing Company | Inhalation device |
US5482030A (en) * | 1994-06-13 | 1996-01-09 | Klein; David | Aerosol and non-aerosol spray counter |
US5482187A (en) | 1993-09-13 | 1996-01-09 | Hygienix, Inc. | Dispenser for viscous substances |
US5547091A (en) * | 1991-11-27 | 1996-08-20 | Colgate-Palmolive Company | Dispensing container snap hinge closure |
US5619984A (en) * | 1989-04-28 | 1997-04-15 | Astra Aktiebolag | Dry powder inhalation device having a powder-loaded elongate carrier |
WO1999025405A1 (en) | 1997-11-14 | 1999-05-27 | Astrazeneca Ab | Inhalation device |
US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6170712B1 (en) * | 1997-05-23 | 2001-01-09 | George Kasboske | Container for holding and dispensing non-rigid material |
-
1999
- 1999-12-24 GB GBGB9930602.9A patent/GB9930602D0/en not_active Ceased
-
2000
- 2000-12-18 EP EP00991978A patent/EP1239906B1/en not_active Expired - Lifetime
- 2000-12-18 AU AU37262/01A patent/AU3726201A/en not_active Abandoned
- 2000-12-18 AT AT00991978T patent/ATE240760T1/en not_active IP Right Cessation
- 2000-12-18 DE DE60002920T patent/DE60002920T2/en not_active Expired - Fee Related
- 2000-12-18 US US10/168,751 patent/US7077129B2/en not_active Expired - Fee Related
- 2000-12-18 JP JP2001548176A patent/JP2003518418A/en active Pending
- 2000-12-18 WO PCT/EP2000/012884 patent/WO2001047590A1/en active IP Right Grant
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2161863A (en) | 1984-07-16 | 1986-01-22 | Realex Corp | Dispenser for pasty products |
US4949875A (en) | 1986-02-18 | 1990-08-21 | Youti Kuo | Dispenser with integrated cover for paste-like material |
US4749351A (en) * | 1986-06-30 | 1988-06-07 | Fgm Enterprises, Inc. | Lighter |
EP0341967A2 (en) | 1988-05-09 | 1989-11-15 | Bespak plc | Dispensing apparatus for nasal administration of an aerosol product |
US5619984A (en) * | 1989-04-28 | 1997-04-15 | Astra Aktiebolag | Dry powder inhalation device having a powder-loaded elongate carrier |
US5408994A (en) * | 1990-11-14 | 1995-04-25 | Minnesota Mining And Manufacturing Company | Inhalation device |
US5547091A (en) * | 1991-11-27 | 1996-08-20 | Colgate-Palmolive Company | Dispensing container snap hinge closure |
US5482187A (en) | 1993-09-13 | 1996-01-09 | Hygienix, Inc. | Dispenser for viscous substances |
US5482030A (en) * | 1994-06-13 | 1996-01-09 | Klein; David | Aerosol and non-aerosol spray counter |
US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6170712B1 (en) * | 1997-05-23 | 2001-01-09 | George Kasboske | Container for holding and dispensing non-rigid material |
WO1999025405A1 (en) | 1997-11-14 | 1999-05-27 | Astrazeneca Ab | Inhalation device |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7651009B2 (en) | 2004-08-16 | 2010-01-26 | Warner Lambert Company Llc | Liquid dispensing device |
US8091545B2 (en) | 2004-12-22 | 2012-01-10 | Schechter Alan M | Apparatus for dispensing pressurized contents |
US20060131350A1 (en) * | 2004-12-22 | 2006-06-22 | Schechter Alan M | Apparatus for dispensing pressurized contents |
US8746242B2 (en) | 2005-07-28 | 2014-06-10 | Glaxo Group Limited | Medicament dispenser |
US20080196718A1 (en) * | 2005-07-28 | 2008-08-21 | Glaxo Group Limited | Medicament Dispenser |
US20090183744A1 (en) * | 2008-01-22 | 2009-07-23 | Paul Graham Hayton | Hand-Held dispensing device |
US8123082B2 (en) | 2008-01-22 | 2012-02-28 | McNeil-AB | Hand-held dispensing device |
USD666097S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666096S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666098S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666493S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD666492S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD666099S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
Also Published As
Publication number | Publication date |
---|---|
EP1239906B1 (en) | 2003-05-21 |
GB9930602D0 (en) | 2000-02-16 |
DE60002920T2 (en) | 2004-01-29 |
AU3726201A (en) | 2001-07-09 |
DE60002920D1 (en) | 2003-06-26 |
WO2001047590A1 (en) | 2001-07-05 |
US20030010337A1 (en) | 2003-01-16 |
EP1239906A1 (en) | 2002-09-18 |
ATE240760T1 (en) | 2003-06-15 |
JP2003518418A (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7077129B2 (en) | Dispenser with biased cover | |
EP1292348B1 (en) | Medicament dispenser | |
US7552728B2 (en) | Drug delivery device | |
US20070056585A1 (en) | Medicament dispenser | |
US6915802B1 (en) | Medicament pack | |
EP1379305B1 (en) | Medicament dispenser | |
MX2008003171A (en) | An inhaler. | |
EP1313523A1 (en) | Inhalation device | |
EP1181068A1 (en) | Medication dispenser | |
EP1603807B1 (en) | Container with a hinge | |
US20060107949A1 (en) | Holder for a dispensing container system | |
Sawatdee et al. | Single-use dry powder inhalers for pulmonary drug delivery | |
GB2367011A (en) | Metered dose inhaler for salmeterol | |
WO2020163468A1 (en) | Dose feedback mechanisms and assemblies for user feedback | |
EP1383457A1 (en) | Medicament dispenser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLAXO GROUP LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSON, GREGOR JOHN, MCLENNAN;TAYLOR, ANTHONY JAMES;REEL/FRAME:017027/0530 Effective date: 20060106 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100718 |